TABLE 1.

Patient characteristics

Patient no.	Age (yr)	HIV subtypea	Time virus undetectable before STI (mo)	Before ART		Baseline of STI trial		Wk 52 HIV RNA (copies/ml)
				Plasma HIV RNA (copies/ml)	CD4 cell count (cells/mm3)	CD4 cell count (cells/mm3)	ARTd
1	41	B	32	561,831	280	723	ZDV-3TC-IDV	—e
2	52	B	26	128,555c	794	1,269	ZDV-3TC-IDV	41,316
3	38	B	31	34,752	1,010	1,115	ZDV-3TC-RTV	—
4	38	B	11	122,902c	259	422	DDI-D4T-NFV	19,127
5	46	B	25	32,608c	388	347	ZDV-3TC-IDV	8,757
6	53	B	32	467,593	11	350	ZDV-3TC-IDV	—
7	33	B	30	16,927	573	832	ZDV-3TC-IDV	4,560
8	55	B	28	162,701c	461	766	ZDV-3TC-IDV	21,848
9	38	B	12	164,772	272	591	D4T-3TC-NFV	51,008
10	35	E/CRF1b	23	11,298	495	777	DDI-D4T-NFV	3,466
11	52	B	22	25,417	302	839	D4T-3TC-NFV	189,929
12	43	B	25	9,404	327	749	ZDV-DDI-NFV	24,587
13	68	A	31	821c	650	670	ZDV-3TC-NFV	286
Mean (range)	46 (33-68)		25 (11-32)	133,814 (821-561,831)	448 (11-1,010)	739 (347-1,269)		36,488 (286-189,929)

^aDetermined as described previously (39).

^bCRF1, circulating recombinant form 1.

^cGeometric mean, because two pretreatment HIV RNA values were available before initiation of ART.

^dZDV, zidovudine; 3TC, lamivudine; IDV, indinavir; DDI, didanosine; RTV, ritonavir; D4T, stavudine; NFV, nelvinafir.

^e—, treatment had to be reinitiated between weeks 40 and 52.